Human Parechovirus 1, 3 and 4 Neutralizing Antibodies in Dutch Mothers and Infants and Their Role in Protection Against Disease

Autor: Dasja Pajkrt, Eveliina Karelehto, Katja C. Wolthers, Gerrit Koen, Menno D. de Jong, Joanne G. Wildenbeest, Sjoerd Rebers, Brenda M. Westerhuis, Kimberley S. M. Benschop, Saskia Bouma-de Jongh
Přispěvatelé: AII - Infectious diseases, Graduate School, Medical Microbiology and Infection Prevention, Amsterdam Reproduction & Development (AR&D), General Paediatrics, Paediatric Infectious Diseases / Rheumatology / Immunology
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Microbiology (medical)
Male
Pediatrics
medicine.medical_specialty
Genotype
case-control study
030106 microbiology
Cell Culture Techniques
Mothers
Parechovirus
Disease
human parechovirus
Antibodies
Viral
03 medical and health sciences
Seroepidemiologic Studies
Medicine
Seroprevalence
Humans
Pediatrics
Perinatology
and Child Health
Prospective Studies
Prospective cohort study
Netherlands
Picornaviridae Infections
biology
business.industry
Human parechovirus
Case-control study
Infant
case–control study
Perinatology
Antibodies
Neutralizing
3. Good health
and Child Health
Titer
030104 developmental biology
Infectious Diseases
maternal antibodies
Case-Control Studies
Pediatrics
Perinatology and Child Health
biology.protein
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
Female
Antibody
business
Maternal-Neonatal Reports
Zdroj: The Pediatric Infectious Disease Journal
Pediatric infectious disease journal, 37(12), 1304-1308. Lippincott Williams and Wilkins
The Pediatric infectious disease journal, 37(12), 1304. Lippincott Williams and Wilkins
ISSN: 1532-0987
0891-3668
Popis: Supplemental Digital Content is available in the text.
Background: Human parechoviruses (HPeVs) are common pathogens in young children, and in the Netherlands, HPeV1, HPeV3 and HPeV4 are the most frequently detected genotypes. HPeV3 in particular has been associated with severe disease in young infants below 3 months of age while the other genotypes more often infect older children and elicit mild symptoms. We investigated if maternal neutralizing antibodies (nAbs) against HPeV1, HPeV3 and HPeV4 protect young Dutch infants from severe disease related to HPeV infection. Methods: We conducted a prospective case–control study of Dutch mother–infant pairs. Thirty-eight HPeV-infected infants and their mothers were included as cases, and 65 HPeV-negative children and their mothers as controls. Results: In control infants, we observed nAb seropositivity rates of 41.4%, 33.3% and 27.6%, with median nAb titers of 1:16, 1:12 and 1:8, against HPeV1, HPeV3 and HPeV4, respectively. In control mothers, nAb seropositivity rates were 84.6%, 55.4% and 60.0% with median nAb titers of 1:128, 1:32 and 1:45 against HPeV1, HPeV3 and HPeV4, respectively. The HPeV3 nAb seroprevalence was significantly lower in HPeV3-infected infants and their mothers (0.0% with P < 0.05 and 10.0% with P < 0.001, respectively). In contrast, no differences in nAb seroprevalence against HPeV1 or HPeV4 could be detected between case and control infants or mothers. Conclusions: Our results suggest that young Dutch infants are protected against severe disease related to HPeV1 and HPeV4 by maternal nAbs, but less so against HPeV3 explaining the distinct age distributions and disease severity profiles of children infected with these HPeV genotypes.
Databáze: OpenAIRE
Externí odkaz: